Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX-6 vs CAPOX in Metastatic Colorectal Carcinoma
NCT07334587Enrolling by invitation
- Sponsor
- Allama Iqbal Medical College
- Start
- Sep 2025
- Primary completion
- Feb 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Randomised trial of capecitabine and oxaliplatin in colorectal cancer (CRC) (2 arms), sponsored by Allama Iqbal Medical College. Primary endpoint: Disease progression at 3 months. Started Sep 2025; status: enrolling by invitation.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07334587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334587.